Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study Comparing AVT16 and Vedolizumab for Adults with Moderate to Severe Ulcerative Colitis

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two treatments for ulcerative colitis, a condition that causes inflammation and sores in the digestive tract. The study involves two medications: AVT16, a proposed biosimilar, and Entyvio (also known as vedolizumab). Both medications are given as a solution through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to compare the effectiveness, safety, and immune response of AVT16 and Entyvio in people aged 18 to 80 who have moderate to severe active ulcerative colitis. Participants will receive either AVT16 or Entyvio, and some may receive a placebo. The study will last for about 46 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, participants will be assessed at various intervals to see how well the treatment is working. This includes checking for clinical responses, which are improvements in symptoms, and clinical remission, which is when symptoms are reduced or disappear. The study will also look at mucosal healing, which is the healing of the lining of the colon, and other health markers like albumin and CRP levels. Safety will be monitored by looking at any side effects or reactions to the infusion. The goal is to determine if AVT16 is as effective and safe as Entyvio for treating ulcerative colitis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    The study involves the administration of two medications: AVT16 and Entyvio. Both are given as a solution for infusion, which means they are administered directly into the bloodstream through a vein.

    The initial phase of the treatment involves receiving the infusion at specific intervals. The first infusion is given at the start of the study, followed by additional infusions at Week 2 and Week 6.

  2. Step 2

    Assessment at week 6

    At Week 6, an assessment is conducted to evaluate the response to the treatment. This includes measuring the reduction in symptoms related to ulcerative colitis, such as rectal bleeding.

    The primary goal is to observe a clinical response, which is defined by a reduction in the severity of symptoms.

  3. Step 3

    Continued treatment and monitoring

    After the initial assessment, the treatment continues with infusions at Weeks 14, 22, 30, 38, and 46.

    Throughout this period, regular monitoring is conducted to assess the effectiveness and safety of the treatment. This includes checking vital signs, conducting laboratory tests, and monitoring for any adverse reactions.

  4. Step 4

    Final assessment at week 52

    At Week 52, a comprehensive assessment is performed to evaluate the overall response to the treatment.

    This includes checking for clinical remission, which means the absence of symptoms, and mucosal healing, which refers to the healing of the lining of the colon.

  5. Step 5

    End of study procedures

    After the final assessment, the study concludes with end-of-study procedures. These may include a final physical examination and laboratory tests to ensure the participant's health and safety.

    Participants are provided with information about the results of the study and any necessary follow-up care.

Who can join the trial?

15 criteria

  • Participants must be men or women aged 18 to 80 years old.
  • Participants must be able to give their consent to join the study.
  • Women can join if they are not pregnant or breastfeeding and meet one of the following conditions:
    • They are not able to have children, which means they have had surgery to remove certain reproductive organs or have not had a menstrual period for 12 months without another medical reason.
    • If they can have children, they must agree to use a reliable form of birth control during the study and for 18 weeks after the last treatment.
    • Men who have partners that can have children can join if they agree to:
      • Not have sexual intercourse as their usual lifestyle choice.
      • Use a condom with spermicide and ensure their partner uses a reliable form of birth control.
      • If their partner is pregnant or breastfeeding, they must use a condom with spermicide or not have sexual intercourse.
      • Not donate sperm during the study and for 18 weeks after the last treatment.
      • Participants must have a diagnosis of **Ulcerative Colitis (UC)**, which is a condition that causes inflammation in the colon.
      • The UC must be moderate to severe in activity.
      • Participants must have evidence of UC.
      • Participants with extensive colitis or pancolitis for more than 8 years, or left-sided colitis for more than 12 years, must have had a colonoscopy within 12 months before the study starts.
      • Participants with a family history of colorectal cancer, personal history of increased risk, age over 50, or other risk factors must be up to date with colorectal cancer checks.
      • Participants must have shown in the past 5 years that they did not respond well, lost response, or could not tolerate at least one treatment for UC.
      • Participants may be taking certain medications like oral 5-aminosalicylic acid (5-ASA), oral corticosteroids, probiotics, antidiarrheals, azathioprine, or 6-mercaptopurine.

Who cannot join the trial?

4 criteria

  • Patients who do not have Moderate to Severe Active Ulcerative Colitis cannot participate. This is a condition where the inner lining of the large intestine and rectum becomes inflamed and develops sores.
  • Patients who are not within the specified age range cannot participate. The age range includes adults and older children.
  • Both males and females can participate, so gender is not a reason for exclusion.
  • Patients who are considered part of a vulnerable population may be excluded. This term refers to groups of people who might be at a higher risk of harm or exploitation, such as children, pregnant women, or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • AVT16

    is a medication being tested as a potential biosimilar to another drug used for treating ulcerative colitis. A biosimilar is a drug that is very similar to an already approved medication, known as the reference product, and is expected to have the same therapeutic effects. In this trial, AVT16 is being compared to see if it works just as well as the reference medication in treating moderate to severe active ulcerative colitis.

  • Entyvio

    is the reference medication in this study. It is an established treatment for ulcerative colitis, a condition that causes inflammation and sores in the digestive tract. Entyvio works by targeting specific proteins in the body to reduce inflammation and help manage symptoms of the disease. The trial aims to compare the effects of AVT16 to those of Entyvio to ensure that the new medication is just as effective and safe for patients.

What is already known about the treatment

AVT16 – AVT16 is administered intravenously and is currently being studied as a biosimilar to Entyvio for the treatment of moderate to severe active ulcerative colitis. It is in the clinical trial phase, aiming to establish its efficacy, safety, and immunogenicity compared to Entyvio. The main therapeutic indication for AVT16 is to manage symptoms of ulcerative colitis, a chronic inflammatory bowel disease. At the molecular level, AVT16 works by targeting specific proteins involved in the inflammatory process, helping to reduce inflammation in the colon. It is classified pharmacologically as a monoclonal antibody.

Investigated diseases

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by inflammation and ulceration of the innermost lining of the colon, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The disease often progresses with periods of exacerbation and remission. During flare-ups, individuals may experience increased urgency to defecate and fatigue. Over time, the inflammation can lead to complications such as strictures or increased risk of colon cancer. The severity of symptoms can vary, with some individuals experiencing mild discomfort and others facing more severe challenges.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507705-34-00Protocol codeAVT16-GL-C01Estimated enrolment832 patientsSponsorAlvotech Swiss AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).